Myovant Sciences Ltd. (MYOV)
| Market Cap | 1.86B |
| Revenue (ttm) | 33.33M |
| Net Income (ttm) | -250.44M |
| Shares Out | 89.74M |
| EPS (ttm) | -2.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $20.54 |
| Previous Close | $21.46 |
| Change ($) | -0.92 |
| Change (%) | -4.29% |
| Day's Open | 21.50 |
| Day's Range | 20.51 - 21.70 |
| Day's Volume | 801,986 |
| 52-Week Range | 6.55 - 27.62 |
Over halfway through the trading day on Wednesday, and the broad markets are making a run into the afternoon.
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Myovant Sciences (NYSE: MYOV), please note that in the first paragraph of the...
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, ch...
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that ORGOVYX™ (relug...
NEW YORK and LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., the majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that Myovant Sciences, a healthcar...
BASEL, Switzerland, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of D...
Myovant Sciences (MYOV) and Pfizer enter collaboration agreement to develop and commercialize relugolix monotherapy and combination regimen for prostate cancer and uterine fibroids, respectively.
Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multip...
Shares of Myovant surged as much as 35% to $30 on Monday after the biopharmaceutical company announced a partnership with Pfizer to develop and commercialize a drug for the treatment of prosta...
Shares of Myovant Sciences soared 27% Monday, after its parent Sumitovant Biopharma unveiled an agreement with Pfizer Inc. to jointly develop a treatment for prostate cancer and women's health...
Myovant Sciences Ltd. (NYSE: MYOV) shares shot up on Monday after the company announced a new collaboration with the pharmaceutical giant Pfizer Inc.
Myovant Sciences Ltd (NYSE: MYOV) stock is adding about one-fourth of its market capitalization Monday following a licensing deal with Pfizer Inc. (NYSE: PFE). What Happened: Myovant announced...
The shares of Myovant Sciences Ltd (NYSE:MYOV) are up 27.2% at $29.08 at last check, gapping to record highs, after the biopharmaceutical concern announced a collaboration with Pfizer (PFE) to...
Myovant and Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada
Shares of Myovant Sciences soared 16% in premarket trade Monday, after its parent Sumitovant Biopharma said Myovant will work with Pfizer Inc. to jointly develop a treatment for men's and wome...
Myovant and Pfizer to jointly develop and commercialize ORGOVYXTM (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and CanadaMyovant to receive an upfron...
BASEL, Switzerland and NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop and commercialize relugo...
Riding strong data, Myovant recently secured FDA approval for relugolix in treating advanced prostate cancer. Under the brand Orgovyx, Myovant will market the said drug as soon as in January.
•ORGOVYX is the first approved therapy in the Sumitovant Biopharma family of companies •ORGOVYX is the first approved therapy in the Sumitovant Biopharma family of companies
BASEL, Switzerland, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that the U.S. Food a...
Investors need to pay close attention to Myovant Sciences (MYOV) stock based on the movements in the options market lately.
BASEL, Switzerland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general pu...
BASEL, Switzerland, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equ...
Myovant Sciences' (MYOV) CEO Lynn Seely on Q2 2020 Results - Earnings Call Transcript
Shares of Myovant Sciences (NYSE:MYOV) rose 0.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 5.06% over the past year to ($0.75), whi...
BASEL, Switzerland, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates an...
As you know, Myovant's shares recently tumbled due to ambiguous Phase 3 data release for its prostate cancer franchise. Upon closer inspection, I believe that relugolix will ultimately be FDA-...
Myovant has positive Phase 3 results in all 3 indications for its main drug relugolix. The stock has taken a huge dive based on disappointing results on a secondary endpoint of the relugolix P...
BASEL, Switzerland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webca...
BASEL, Switzerland, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the presentation of ...
BASEL, Switzerland, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of R...
Myovant Sciences posted poor trial data for part of a Phase 3 study for a prostate cancer treatment that awaits key FDA action later this year, and MYOV stock plummeted out of a buy zone. The ...
Atlanta, Georgia--(Newsfile Corp. - September 29, 2020) - Holzer & Holzer, LLC is investigating whether Myovant Sciences Ltd. (NYSE: MYOV) ("Myovant" or the "Company") complied with federal ...
BASEL, Switzerland, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced results of an add...
Investors need to pay close attention to Myovant Sciences (MYOV) stock based on the movements in the options market lately.
BASEL, Switzerland, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the launch of its...
The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.
Myovant Reports Data, And Other News: The Good, Bad And Ugly Of Biopharma
BASEL, Switzerland, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the presentation ...
BASEL, Switzerland, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that its New Drug ...
BASEL, Switzerland, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates ...
Myovant Sciences Has Limited Downside At Its Current Price
BASEL, Switzerland, July 06, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the presentation o...
CHICAGO, Ill.; SAN MATEO, Calif.; LOS ANGELES, Calif.; and BASEL, Switzerland, June 30, 2020 (GLOBE NEWSWIRE) -- BlackDoctor.org, Evidation Health, Movember, and Myovant Sciences (NYSE: MYOV...
Myovant (MYOV) reports positive top-line data from the phase III study on the relugolix combination therapy in women suffering from pain associated with endometriosis.
Shares of Myovant popped to a six-month high Tuesday after the biotech's endometriosis treatment succeeded in a Phase 3 test. This puts Myovant up against Neurocrine and AbbVie.
Shares of Myovant Sciences Ltd. MYOV, +4.43% gained 7% in premarket trading on Tuesday after the drugmaker said a late-stage clinical trial for its experimental endometriosis drug hit its prim...
BASEL, Switzerland, June 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced top-line results f...
About MYOV
Myovant Sciences, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as pa... [Read more...]
| Industry Biotechnology | IPO Date Oct 27, 2016 |
| Stock Exchange NYSE | Ticker Symbol MYOV |
Analyst Forecasts
According to 8 analysts, the average rating for MYOV stock is "Buy." The 12-month stock price forecast is 36.14, which is an increase of 75.95% from the latest price.